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ABSTRACT 
Since last decade drugs through skin hasreceived great attention of many researchers. The aim of 
present study was designed to develop a suitable matrix type transdermal drug delivery system 
(TDDS) of Losartan potassium using blends of different polymeric combinations of 
polyvinylpyrrolidone K30 (PVP K30) and ethylcellulose (EC), hydroxypropyl methyl cellulose 
and chitosan. Physical studies including thickness, folding endurance moisture content, tensile 
strength and flatness were performed on all formulations. In-vitro diffusion study of 10 hrs was 
performed by means of Franz diffusion cell. All theformulations were found to be suitable for 
formulating in terms of physicochemical characteristics. Stability study performed on selective 
batch, TP1 for 12 weeks at different temperatureindicates stability of  transdermal patches at 
room temperature. 
Present study concluded that Losartan potassium can be formulated into the transdermal matrix 
type patches to sustain its release characteristics. Polymeric composition of batch TP1 (PVP K30 
: Chitosan:: 70:30) was found to be the best choice for manufacturing transdermal patches of 
Losartan potassium among the formulations studied. 
Keywords: Losartan potassium, skin, transdermal drug delivery system,Franz diffusion cell, in-
vitro diffusion. 
 
INTRODUCTION 
Skin is an effective medium from which absorption of the drug takesplace and enters into 
systematic circulation over a period of time
1
. Transport of compounds via skin is considered to 
be a complex phenomenon, which allows the passage of certain chemicals into and across the 
skin. Transdermal drug delivery is the noninvasive delivery of medications from the surface of 
skin the largest and most accessible organ of human body through its layers, to the circulatory 
system
2
.  
Transdermal patches are designed to slowly deliver the active substance(s) through the intact 
skin, resulting in a prolonged and adequately constant systemic absorptionrate, reduced number 
of doses and side effects of drug and improved therapeutic efficacy
3
. 
At present scenario more than 74% of drugs are taken orally and are found not to be as valuable 
as desired. To advance such characters transdermal drug delivery system was introduced. A 
Transdermal patch is an adhesive patch that has a coating of drug that is placed on the skin to 
deliver specific dose into the systemic circulation over a period of time
4
. 
Losartan potassium is an orally active angiotensin-II receptor antagonist used in the treatment of 
hypertension due to mainly blockade of AT1 receptor
5,6,7
.  
In present work Losartan potassium was selected for development and evaluation of matrix-type 
transdermal patches in order to improve its bioavailabilityand reduce frequency of 
administration. 
 
MATERIALS AND METHODS 
Losartan potassium was obtained from BondChemical Industries Limited, Lagos, 
Polyvinylpyrrolidone K30 and HPMC K100 was received from Afrik Pharmaceuticals Limited, 
Nigeria. Ethyl cellulose, and Chitosan from Dana Drugs Limited, Nigeria. Castor oil, and 
 propylene glycol was received from  Food and Pharma Nig. Limited, Lagos, Nigeria. All other 
reagents used were of analytical grades. 
Preparation of the Losartan potassium transdermal patches 
Polymers in different ratio (table-1) were taken with plasticizerand Losartan potassium and 
dissolved in different solvents. Solution was then poured onto a glass petri dish and then placed 
in an oven. An inverted funnel was placed on the petri dish to facilitate the evaporation of the 
solvent at the controlled rate over the drying periods of 12 hrs at 40 C. Thefilm thus formed was 
collected with a sharp razor blade
8
. 
Table-1: Compositions of the Losartan potassium transdermal patches 
Code Polymers ratio (%) Solvent Plasticizer 
(20%) 
Propylene glycol 
(Permeation 
enhancer) 
TP1 PVP K30 : Chitosan:: 
70:30   
Dichloromethane 
(2% w/v) 
Castor oil 30% 
TP2 PVP K30: Chitosan:: 
30:70   
Dichloromethane 
(2% w/v) 
Glycerine - 
TP3 HPMC: Ethyl 
cellulose::70:30 
Acetic acid (1 % 
w/v)  
Castor oil - 
TP4 HPMC: Ethyl 
cellulose::30:70 
Acetic acid (1 % 
w/v) 
Glycerine 30% 
 
EVALUATION OF TRANSDERMAL PATCHES 
Determination of patch thickness 
Patch thickness of Losartan potassium transdermal patches was measured using a digital 
micrometer (Mitutoyo, Japan). A mean of three readings was obtained
9
.  
Weight Variation: Uniformity of weights of Losartan potassium transdermal patches were 
determined by weighing five matrices of each formulation. Aftereach film unit was weighed 
individually on a digital balance, the average weight of film was taken as the weight of the 
film
10
. 
Evaluation of drug content 
A known area of each patch was weighed accurately and dissolved in 2 ml chloroform 
followed by dilution with distilled water and then filtered. Drug content was analyzed by UV 
spectrophotometer (PerkinElmer, USA) at 250 nm. A drug-free film was usedas control. A 
mean of three readings was recorded. The results are reported as mean of six readings
11
. 
Folding Endurance:  
Three Losartan potassium transdermal patches of each batch were taken for this study. Folding 
endurance was determined by repeatedly folding one film at the same place till it break. The 
number of times the film could be folded at the same place without breakinggave the value of 
folding endurance
12
.                                                                                                                                                                  
Flatness  
Longitudinal  strips of 1.8 cm in  length were used out from the prepared Losartan potassium 
transdermal patches and then variation in the lengthsdue to the non-uniformity in flatness was 
measured
13
. 
Flatness was calculated by measuring constriction of strips and a zero percent constriction was 
considered to be equal to a hundred percent flatness. 
Constriction (%)  =(l1¬ – l2 )/(  l2 ) X100 
 Where, l1 = final length of each strip, and   l2 = initial length 
Determination of tensile strength 
The tensile strength of Losartan potassium transdermal patches was evaluated using Instron 
4204 Tensile tester, with a 50 KN load cell (Instron, UK). Six samples of each formulation were 
tested at an extension speed of 5 mm/min
14
. The test was carried out at 25 ± 2 °C and 56 ± 2 % 
RH and tensile strength calculated – 
τ=(Lmax )/(Ai ) 
Where τ is the tensile strength; Lmax is the maximum load; and Ai is the initial cross sectional 
area of the sample.  
Measurement of moisture content 
Each patch was weighed and kept in a desiccator containing fused calcium chloride at 40 °C for 
24 h. The patches were reweighed until a constant weight was obtained. A mean of three 
readings was taken
15
. The results are reported as mean of six readings. 
% Moisture content  =(Initial Weight – Final Weight )/( Initial Weight) X100 
Water vapor transmission rate: 
Glass vials of 5 ml capacity were washed thoroughly and dried to a constant weight in an oven. 
About 2 g of fused calcium chloride was taken in the vials and the polymer films of 2.25 cm
2
 
were fixed over the brim with the help of an adhesive tape. Then the vials were weighed and 
stored in a humidity chamber of 80-90 % RH condition for a period of 24 h 7, 23. The vials were 
removed and weighed at 24 h time intervals to note down the weight gain
16
. 
WVTR =(Final Weight – Initial Weight )/( Time x Area  ) X100 
Table-2:  Physical Characterization of Losartan potassium transdermal patches 
 TP1 TP2 TP3 TP4 
Physical Appearance Uniform, opaque, 
slightly sticky, 
flexible 
Uniform, opaque, 
slightly sticky, flexible 
 
Uniform, 
transluscent, 
slightly sticky, 
flexible 
 
Uniform, 
transluscent, 
slightly sticky, 
flexible 
 
Thickness (mm)  0.30 ± 0.37 0.31 ± 0.27 0.32 ± 0.08 0.33 ± 0.09 
Weight (mg) 
45.3 ± 0.28 
43.7 ± 0.34 42.3 ± 0.26 
46.57 ± 0.13 
% Drug content 96.77± 0.31 95.42± 0.18 96.42± 0.42 94.81± 0.12 
Folding endurance > 288 > 285 > 122 > 150 
Flatness 
100% 100% 100% 100% 
Tensile strength (MPa) 4.39± 0.58 
5.21± 0.32 
6.37± 0.43 5.47± 0.09 
% Moisture Content 
3.44 ± 0.25 
2.56 ± 0.26 2.78 ± 0.25 2.88 ± 0.25 
WVTR (g/cm
2
/hrs 1.621x10
-4
± 0.12 
1.489 x10
-4
± 0.27 
1.543x10
-4
±0.08 1.443x10
-4
± 0.12 
 
In vitro diffusion study 
The diffusion studies of Losartan potassium transdermal patches were done to get an idea of 
permeation of drug through barrier from the transdermal system
17
. Franz-diffusion cell which is 
also called Keshary – Chein cellwas used to study the in-vitro release profile for a 10 hrs study. 
The cell consisted of sampling port and temperature maintaining jacket
18
. The outlet and inlet 
was connected with latex tube so the jacket had stagnant water inside and heat was provided by 
hot plate. Receptor compartment, which was maintained at 37
0
C. The patches of diameter of 2 
cm. Every hour 1 ml of the receptor fluid was withdrawn and replaced with 1 ml of fresh drug 
free buffer (pH 7.4) solution to maintain constant volume. Thewithdrawn sample was analyzed 
spectrophotometrically at 250 nm. 
  
 
Figure-1: In-vitro diffusion profile of Losartan potassium transdermal patches 
Stability Study:  
The transdermal patches of Losartan potassium were subjected toaccelerated stability study at 
(40°C/75% RH) conditions for 90 days. The patches were packed in aluminum foil and kept at 
accelerated conditions. The patches were analyzed for drug content at 0, 30, 60 and 90 days 
respectively by a UV spectrophotometer method
19
. 
Statistical analysis 
the results obtained were treated statistically using one-way analysis of variance (ANOVA). 
Post-hoc Tukey-HSD (Honestly Significant Difference) test wasperformed when there was a 
statistically significant difference, which was set at p ≤ 0.05. 
 
Figure 2: Stability study of optimized Losartan potassium transdermal patches of batch 
TP1  
 
RESULTS AND DISCUSSION 
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 Four transdermal patches formulations of Losartan potassium were prepared by using different 
polymers i.e. PVP K30, EC, chitosan, HPMC in different ratio.  Dichloromethane (2% w/v) and 
acetic acid (1 % w/v) were used as the solvent based on the solubility of the polymers. Propylene 
glycol (30%) was used as permeation enhancer. Thickness lies in the range of 0.30 to 0.33 mm. 
Average thickness was almost uniform within same formulation a small variation in thickness 
was observed with different formulations. Thevariations in thickness may be due to viscosity of 
polymer solutions of different formulations. Patch thickness should also be appropriate because 
increased film thickness will increase compaction and reduce the mobility of molecules, which 
can decrease drug release from the patch
20
. Mean drug content of in all the patches was found to 
be greater than 94.81 %. The weight of patches lies in the range of 42.3 to 46.57 mg (table 2).  
The % drug content lies in the range of 93.81 to 96.77. Content uniformity studies proved that 
the amount of Losartan potassium in each patch of 2.009 cm
2
 was found to be fairly uniform.  
Percent moisture content was found to be in the range of 2.56 to 3.44. Moisture 
content depend on type and concentration of plasticizer
21
. In present study castor oil and glycerin 
were used as plasticizer. Since patch with too much of water is prone to microbial growth while 
too less amount of water is prone to cracking and chances to absorb water from our skin
22
. 
Therefore, it is important to perform physicochemical studies in order to determine the suitable 
patch therapy over longer period of time without losing integrity of the polymeric composition of 
the transdermal patches. The folding endurance represents the elasticity of the patches. 
Formulation of batches TP1 and TP2 has shown higher folding enduarance (greater than 280) 
reason may be elastic nature of chitosan present in these two batches. Thistest is performed to 
check the suitability of sample to withstand folding and brittleness
23
. 
Tensile strength lies in the range of 4.39-6.37 MPa. According to American Society for Testing 
Materials (ASTM), materials with tensile strength > 4.0 MPa possess an elastic characteristic
24
. 
Patches should be elastic in order to withstand external forces such as wear and tear during 
handling, storage or use. Water vapor transmission rate was found tobe maximum for 
formulation of batch TP1. The in-vitro diffusion of Losartan potassium transdermal patches 
formulation was studied using locally fabricated Franz diffusion cell. The cumulative percent 
drug release after 10 hrs in between 38.41 to 80.41%. Largest in batch code TP1 (80.41%) 
indicates the effects of propylene glycol as permeation enhancer. Rapid drug leakage was 
observed during the initial phase.  However, after that a slow release occurred. In general the 
release of the drug depends upon hydrophobic and insoluble nature of thepolymers used
25
. The 
drug release increases on increasing the concentration of hydrophilic polymer in the polymer 
matrix. Drug release increased with increase in the content of PVP K30 due to the hydrophilicity 
of PVP K30 which facilitates water absorption thus promoting drug dissolution and drug release 
from the patch. Furthermore, as PVP leaches out, pores are created in the matrix for drug to 
diffuse out of the patch; thus, drug release is increased. 
Stability studies performed on optimized formulations TP1 shows 97.62% drug content at 
refrigeration condition, 92.52% drug content at oven condition and 98.43% drug content at room 
temperature during the studies performed for 12 weeks (figure 2). Hence it is concluded from the 
obtained data that the optimum storage condition for transdermalpatches was found to be room 
temperature. 
CONCLUSION 
Transdermal drug delivery systems continue to deliver patients’ increased compliance by providing 
predictable and reliable therapeutic dosages. The prepared transdermal drug delivery system of 
Losartan potassium using different polymers such as HPMC, EC, Chitosan and PVP had shown 
 good promising result for all the evaluated parameters. Based on the in-vitrodrug release and 
drug content, formulation TP1 was concluded as an optimized formulation. 
The studies concluded that proper combination of hydrophilic and hydrophobic polymers is 
required in formulation development of transdermal patches ofLosartan potassium. 
However, further in vivo and in vitro investigations are required. 
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